Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of Dimebon in mild-to-moderate Huntington's disease
NL-OMON35412Phase 3Active, not recruiting
- Sponsor
- Medivation
- Start
- Mar 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Huntington disease (HD) comparing Dimebon with Placebo (2 arms). Primary endpoints: Change in cognition measured by Mini-Mental State Examination and Global function measured by Clinician's Interview-Based Impression of Change plus caregiver input. Started Mar 2010; status: active, not recruiting.
02
Drugs
latrepirdine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON35412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35412.